ArticleBMC gastroenterology2026
Tumor mitochondrial respiration rather than glycolytic activity predicts recurrence in colorectal cancer: an ex vivo bioenergetic profiling study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic reprogramming is a recognized hallmark of colorectal cancer (CRC), yet whether intratumoral bioenergetic capacity directly influences clinical outcomes remains unclear. In particular, the relative prognostic contributions of mitochondrial respiration and glycolytic activity to postoperative recurrence have not been systematically evaluated. This study aimed to determine whether tumor oxygen consumption rate (OCR) or extracellular acidification rate (ECAR), measured ex vivo by Seahorse bioenergetic assays, is associated with recurrence-free survival (RFS) and overall survival (OS) in patients with resected CRC.
methodsIn a single-center prospective cohort of 104 patients who underwent surgical resection for CRC between 2012 and 2017, paired tumor and adjacent normal mucosal specimens were analyzed using the Seahorse XF24 analyzer to quantify basal OCR and ECAR. Tumors were stratified by cohort median values and by receiver operating characteristic (ROC)-derived cutoffs optimized for recurrence prediction. Associations with RFS and OS were assessed using Kaplan-Meier analysis and Cox proportional hazards regression, adjusting for clinicopathological covariates.
resultsOver a median follow-up of 69 months, tumor OCR was significantly lower than that of adjacent normal mucosa (p < 0.001), whereas ECAR did not differ between paired tissues. OCR and ECAR were positively correlated within tumors (R² = 0.268, p < 0.001). In multivariate Cox regression, higher tumor OCR was independently associated with shorter RFS, both as a continuous variable (hazard ratio 1.455 per 1000-unit increase, p = 0.010) and when dichotomized by median or ROC-derived cutoffs (all p < 0.05). ROC analysis demonstrated moderate discriminatory ability for OCR (area under the curve 0.650), whereas ECAR showed no prognostic value. No bioenergetic parameter was significantly associated with OS.
conclusionsIntratumoral mitochondrial respiratory capacity, rather than glycolytic activity, independently predicts recurrence in resected CRC. These findings suggest that tumor OCR may serve as a functional metabolic biomarker for recurrence risk stratification, warranting prospective validation in independent cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.